Laboratory of Medical Investigation, Urology Department - LIM55, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Clinics (Sao Paulo). 2013;68(3):297-303. doi: 10.6061/clinics/2013(03)oa03.
Bladder cancer represents 3% of all carcinomas in the Brazilian population and ranks second in incidence among urological tumors, after prostate cancer. The loss of p53 function is the main genetic alteration related to the development of high-grade muscle-invasive disease. Prima-1 is a small molecule that restores tumor suppressor function to mutant p53 and induces cancer cell death in various cancer types. Our aim was to investigate the ability of Prima-1 to induce apoptosis after DNA damage in bladder cancer cell lines.
The therapeutic effect of Prima-1 was studied in two bladder cancer cell lines: T24, which is characterized by a p53 mutation, and RT4, which is the wild-type for the p53 gene. Morphological features of apoptosis induced by p53, including mitochondrial membrane potential changes and the expression of thirteen genes involved in apoptosis, were assessed by microscopic observation and quantitative real-time PCR (qRT-PCR).
Prima-1 was able to reactivate p53 function in the T24 (p53 mt) bladder cancer cell line and promote apoptosis via the induction of Bax and Puma expression, activation of the caspase cascade and disruption of the mitochondrial membrane in a BAK-independent manner.
Prima-1 is able to restore the transcriptional activity of p53. Experimental studies in vivo may be conducted to test this molecule as a new therapeutic agent for urothelial carcinomas of the bladder, which characteristically harbor p53 mutations.
膀胱癌占巴西人群所有癌种的 3%,在泌尿系统肿瘤中发病率仅次于前列腺癌,排名第二。p53 功能丧失是与高级别肌层浸润性疾病发展相关的主要遗传改变。Prima-1 是一种小分子,可恢复突变型 p53 的肿瘤抑制功能,并诱导多种癌症类型的癌细胞死亡。我们的目的是研究 Prima-1 在膀胱癌细胞系中诱导 DNA 损伤后细胞凋亡的能力。
在两种膀胱癌细胞系 T24(p53 突变型)和 RT4(p53 野生型)中研究了 Prima-1 的治疗效果。通过显微镜观察和实时定量 PCR(qRT-PCR)评估了 p53 诱导的细胞凋亡的形态学特征,包括线粒体膜电位变化和 13 个与凋亡相关的基因的表达。
Prima-1 能够在 T24(p53 mt)膀胱癌细胞系中重新激活 p53 功能,并通过诱导 Bax 和 Puma 表达、激活半胱天冬酶级联反应以及非 BAK 依赖性破坏线粒体膜来促进细胞凋亡。
Prima-1 能够恢复 p53 的转录活性。可以进行体内实验研究来测试这种分子作为一种新的治疗药物,用于膀胱癌,其特征是存在 p53 突变。